Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
When Context Changes What SR1 Results Mean
2026-11-21
StemRegenin 1 and a large single-cell CRISPR study address related but nonidentical questions in human hematopoiesis. Comparing their models, interventions, and readouts shows why cell expansion, lineage output, engraftment, and regenerative capacity should not be treated as interchangeable evidence.
What the HSPC CRISPR Atlas Shows About SR1
2026-11-20
A literature-focused interpretation of a single-cell CRISPR atlas in human hematopoietic stem and progenitor cells, with careful separation of genetic evidence about epigenetic regulators from pharmacological claims associated with StemRegenin 1 (SR1).
A Functional Atlas of Human HSPC Fate
2026-11-20
A paper-centered interpretation of a single-cell CRISPR atlas that connects epigenetic regulator perturbations with cell states, transcriptional programs, lineage output, long-term repopulating behavior, and candidate dependencies in acute myeloid leukemia.
Astrocytes, S2 Circuits, and Tactile Categorization
2026-11-19
A mouse study links chemogenetic modulation of secondary somatosensory-cortex astrocytes with improved vibrotactile categorization and coordinated changes in neuronal gain, adaptation, and sensory signal-to-noise. The findings support a circuit- and task-specific role for astrocytes while leaving the physiological generality of the manipulation unresolved.
How BR Signaling Is Rewired in the Anther
2026-11-19
A recent Arabidopsis study places BSK kinases, BIN2, and BZR transcription factors in a repurposed pathway downstream of EMS1. The comparison of higher-order mutants, developmental phenotypes, protein interactions, and CYCB1;1 measurements supports a signaling architecture for anther patterning, while leaving important questions about spatial specificity and phosphatase action unresolved.
How MRS 2578 Reveals P2Y6 Signaling
2026-11-18
MRS 2578 is described as an insurmountable antagonist of the P2Y6 nucleotide receptor. Its reported effects connect receptor-level inhibition with reduced inositol-phosphate signaling and loss of UDP-associated cellular protection, while also illustrating why functional potency values and selectivity claims must remain tied to their experimental models.
What EP4 Blockade Reveals About Disease Biology
2026-11-18
ONO-AE3-208 is documented as an EP4 antagonist whose reported effects connect prostaglandin signaling with cancer-cell motility, invasion, metastasis, and vascular-wall remodeling. The findings support a preclinical mechanism hypothesis, but each assay measures a different biological level and does not by itself establish clinical efficacy.
How EP4 Blockade Changes PGE2 Signaling
2026-11-17
CJ-42794 is documented as a selective EP4 antagonist whose receptor binding, cellular signaling, inflammatory readout, and tissue-repair effects illustrate how one prostaglandin pathway can produce different outcomes across biological levels.
How EP4 Antagonism Changes PGE2 Signaling
2026-11-17
CJ-42794 is described as a selective EP4 antagonist whose reported effects connect receptor binding with cAMP signaling, inflammatory cytokine output, and gastric repair. The key interpretive question is how strongly these measurements support EP4-specific biological conclusions.
Co-registering Cardiac Structure and Electrophysiology
2026-11-16
A proof-of-concept study combined panoramic hyperspectral imaging with optical mapping in infarcted rat hearts, linking epicardial tissue composition to local electrical activity through a shared three-dimensional surface representation.
What EP4 Blockade Reveals About Inflammation
2026-11-16
L-161,982 provides a conceptual link between EP4 signaling, ERK phosphorylation, epithelial-cell proliferation, and inflammatory disease phenotypes. The reported findings support pathway involvement in the models described, while leaving the size, specificity, and clinical relevance of those effects unresolved.
How IGF-IR Inhibition Changes Cancer Cell Signaling
2026-11-15
NVP-AEW541 is documented as a selective IGF-IR kinase inhibitor with a reported IC50 of 0.086 μM. Its documented effects connect receptor autophosphorylation with altered cell-cycle behavior, apoptosis, proliferation, and context-dependent radiosensitization, while also illustrating why biochemical potency does not by itself predict cellular response.
How to Interpret ML-193 GPR55 Evidence
2026-11-14
ML-193 findings form a mechanistic chain from GPR55 antagonism and β-arrestin trafficking to neuronal calcium changes and pain-related behavior in rats. Each readout answers a different question, so the reported approximately 221 nM IC50 supports assay-specific antagonism rather than direct evidence of human analgesic efficacy.
Why CB1 Binding and Function Can Diverge
2026-11-13
Org 27569 illustrates how an allosteric ligand can increase agonist binding to CB1 while reducing receptor-mediated function. The apparent contradiction reflects different biological readouts: purified-receptor binding measures ligand cooperativity, whereas tissue contraction assays also depend on receptor conformation, signaling, and downstream physiology.
How 5-HT3 Blockade Relates to Antiemesis
2026-11-13
Granisetron HCl is identified as a 5-HT3 receptor antagonist with antiemetic activity. The useful scientific question is how an interaction at an ion channel can produce an organism-level reduction in emetic responses, and what evidence is needed to distinguish a plausible mechanism from product-specific efficacy.